Back to top
more

Rigel Pharmaceuticals (RIGL)

(Delayed Data from NSDQ)

$1.14 USD

1.14
519,998

+0.06 (5.07%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $1.14 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -16.67% and 4.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?

by Zacks Equity Research

Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.

Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now

by Zacks Equity Research

Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.

Here's Why You Should Invest in Aquestive (AQST) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.

Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva

by Zacks Equity Research

The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.

Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?

by Zacks Equity Research

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

Best Momentum Stock to Buy for December 8th

by Zacks Equity Research

BRSP and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2023.

New Strong Buy Stocks for November 28th

by Zacks Equity Research

AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.

Best Momentum Stocks to Buy for November 22nd

by Zacks Equity Research

BWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023.

New Strong Buy Stocks for November 22nd

by Zacks Equity Research

RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 1.98% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 11.11% and 7.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Pacira (PCRX) Q1 Earnings Expected to Decline

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

by Zacks Equity Research

The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More

by Zacks Equity Research

Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.

Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

by Zacks Equity Research

Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.